Department of Orthopedics and Physical Rehabilitation; Department of Surgery
Immune System Diseases | Musculoskeletal Diseases | Rheumatology | Skin and Connective Tissue Diseases | Therapeutics
To evaluate the impact of rituximab on patient-reported outcomes (PROs) in a US-based observational cohort of patients with rheumatoid arthritis (RA). Patients with active RA, prior exposure to > /=1 tumor necrosis factor inhibitor (TNFi) and who newly initiated rituximab were identified. Changes in PROs were assessed 1 year after rituximab initiation. PRO measures included Clinical Disease Activity Index (CDAI); patient global disease activity, pain and fatigue (visual analog score; 0-100); morning stiffness (hours); modified Health Assessment Questionnaire (mHAQ; 0-3); and EuroQoL EQ-5D. Of the 667 patients who newly initiated rituximab, baseline PRO and clinical measures indicated that patients were substantially impacted by their RA disease and quality of life; 54% of patients had high disease activity. One year after rituximab initiation, 49.0, 47.1, 49.8, and 23.2% of patients reported clinically meaningful improvements in patient global, pain, fatigue, and mHAQ, respectively. Morning stiffness and EuroQol EQ-5D domains improved in 48 and 19-32% of patients, respectively. These real-world registry data demonstrated that patients with long-standing, refractory RA experienced improvements in PROs 1 year after initiating rituximab.
Biologics, Patient-reported outcomes, Rheumatoid arthritis, Rituximab
Rights and Permissions
© The Author(s) 2017. This article is an open access publication.
DOI of Published Version
Clin Rheumatol. 2017 Sep;36(9):2135-2140. doi: 10.1007/s10067-017-3742-2. Epub 2017 Jul 17. Link to article on publisher's site
Harrold LR, John A, Best J, Zlotnick S, Karki C, Li Y, Greenberg JD, Kremer JM. (2017). Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry. Open Access Articles. https://doi.org/10.1007/s10067-017-3742-2. Retrieved from https://escholarship.umassmed.edu/oapubs/3212
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.